BFM
SLDB icon

Boothbay Fund Management’s Solid Biosciences SLDB Stock Holding History

Boothbay Fund Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23
Closed -$359K – 978
2019
Q3 		$359K Buy
+23
New +$2.6K 0.03% 529

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boothbay Fund Management's SLDB Position: Q2 2026 in Review

Boothbay Fund Management reduced its Solid Biosciences (SLDB) stake by 77% in Q2 2026, selling an estimated $509K and leaving 19,949 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Boothbay Fund Management first reported a position in SLDB in Q4 2019 and has held it in 13 quarters since. The position peaked at $627K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Boothbay Fund Management held 19,949 shares of Solid Biosciences worth $199K as of Q2 2026.
  • Boothbay Fund Management sold 67,100 Solid Biosciences shares in Q2 2026, an estimated $509K.
  • Solid Biosciences made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1937 holding.
  • Boothbay Fund Management first reported a position in Solid Biosciences in Q4 2019 and has held it in 13 quarters since.
  • Boothbay Fund Management's Solid Biosciences position peaked at $627K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.